Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use.

@article{Zazzali2015RiskOC,
  title={Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use.},
  author={James L. Zazzali and Michael S. Broder and Theodore A. Omachi and Eunice Chang and Gordon H. Sun and Karina Raimundo},
  journal={Allergy and asthma proceedings},
  year={2015},
  volume={36 4},
  pages={
          268-74
        }
}
BACKGROUND Oral corticosteroids (OCS) are a mainstay of asthma treatment. Their use increases the risk of various corticosteroid-related adverse events, but the extent of risk is poorly characterized. OBJECTIVE To determine the incremental risk of possible corticosteroid-related adverse events (AE) in asthma among patients with high OCS use compared with patients who do not use OCS. METHODS Patients with asthma in a commercial health care claims data base who were high-OCS users (≥30 days… 
View on PubMed
pharllc.com
50 Citations
Highly Influential Citations
2
Background Citations
11
Methods Citations
2
Results Citations
1

50 Citations

Citation Type

Citation Type

Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis
TLDR
Although OCS may help control asthma and manage exacerbations, OCS side effects may result in additional health care resource use and costs, highlighting the need for OCS-sparing asthma therapies.
A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma
TLDR
The use of OCS in the management of asthma is associated with a higher risk of complications, and this risk is higher as the OCS dose increases.
Prevalence of oral corticosteroid use in the German severe asthma population
TLDR
The analyses show that OCSs are frequently prescribed in patients receiving HD-ICS/LABAs because of severe asthma and are they are frequently associated with adverse effects commonly reported with steroid usage.
Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis
TLDR
Oral prednisolone use is associated with infections, gastrointestinal, neuropsychiatric, ocular, cardiovascular, metabolic, and bone-related complications among adult asthma patients.
Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature
TLDR
It was found that the risk of developing various OCS-related complications was higher for patients with long-term exposure to OCS compared with control groups, and one should aim at short-term use with the lowest effective dose and start tapering as soon as possible until OCS therapy is terminated.
Burden of systemic glucocorticoid-related complications in severe asthma
TLDR
These findings confirm the risk associated with chronic use of SGCs, irrespective of dose level, and highlight the need for new SGC-sparing treatment strategies for patients with severe asthma.
Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Future Risks in Patients With Severe Asthma
TLDR
As future risk is poorly perceived by controlled asthmatics, this review focuses on the risk in patients with ‘controlled’ severe asthma and it is likely that long-term OCS therapy may not prevent future asthma progression, including lung function decline.
Increased mortality in patients with corticosteroid-dependent asthma: a nationwide population-based study
TLDR
Chronic use of systemic corticosteroid (CS) was associated with increased risk of mortality in patients with asthma, with a significant dose–response relationship between systemic CS use and long-term mortality.
Systemic Corticosteroid-Related Complications and Costs in Adults with Persistent Asthma.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 17 REFERENCES
The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use.
Population-based assessment of adverse events associated with long-term glucocorticoid use.
TLDR
The prevalence of 8 commonly attributed self-reported glucocorticoid-associated AEs was significantly associated with cumulative and average glucoc Corticoid dose in a dose-dependent fashion, particularly among users of low-dose therapy.
Defining High Oral Corticosteroid Use in Asthma Patients
TLDR
The most commonly reported duration of OCS was 6 days, which is representative of how OCS bursts are administered, suggesting that OCS prescriptions were often given in short 6-day increments as opposed to long 30-day batches.
The epidemiology of glucocorticoid-associated adverse events
TLDR
The introduction of glucocorticoid therapy by Dr Philip Hench in the 1950s revolutionized the treatment of rheumatic and inflammatory disease and still remains an important component of therapy for a variety of diseases.
The natural history of community-acquired pneumonia in COPD patients: a population database analysis.
Asthma in older patients: factors associated with hospitalization.
TLDR
Care appeared to be better for the older patients compared with the younger, including more frequent use of inhaled corticosteroids, greater self-management knowledge, and fewer reported barriers to care.
The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysis
TLDR
It is concluded that oral corticosteroid treatment using more than 5 mg (of prednisolone or equivalent) daily leads to a reduction in bone mineral density and a rapid increase in the risk of fracture during the treatment period.
Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease.
TLDR
Multimorbidity is common in patients with COPD, and different comorbidite clusters can be identified, and low-grade systemic inflammation is mostly comparable among comor bidities.
Patterns and predictors of statin prescription in patients with type 2 diabetes
TLDR
The majority of patients with type 2 diabetes are not receiving statins, and the predominant factors determining statin prescription are the patient's prevention status and, in primary prevention, estimated cardiovascular risk.
Trends in antihypertensive and lipid-lowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?
TLDR
Trends in drug utilisation were consistent with the evolving evidence base but there were wide variations inDrug utilisation between practices, suggesting a more consistent approach to drug selection might be associated with improved patient outcomes.
...
1
2
...